Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any acute myeloid leukemia that has the chromosomal anomaly t(2;12). (A cytogenetic abnormality that involves a translocation between chromosomes 2 and 12.)
Biomarker and diagnostic research for acute myeloid leukemia, t(2;12) has been reported in the published literature.
No clinical trials have been registered for acute myeloid leukemia, t(2;12).
3 publications have been identified in PubMed for acute myeloid leukemia, t(2;12). Research spans Epidemiology / Natural History (67%) and Diagnostic / Biomarker (33%).
Marchi F (2025). [PMID: 40730747](https://pubmed.ncbi.nlm.nih.gov/40730747/). *Nature communications*. [Diagnostic / Biomarker]
Yadav V (2024). [PMID: 39371707](https://pubmed.ncbi.nlm.nih.gov/39371707/). *Cureus*. [Epidemiology / Natural History]
Liu L (2024). [PMID: 39103751](https://pubmed.ncbi.nlm.nih.gov/39103751/). *BMC Cancer*. [Epidemiology / Natural History]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 6:00 PM UTC
Common questions about acute myeloid leukemia, t(2;12)